The study investigated the effects of androgen deprivation therapy on diabetes control in men with prostate cancer.

This study evaluated whether there was an association between statin (a type of cholesterol-lowering medication) use and prostate cancer (PCa) mortality. This study found that stain use resulted in lower rates of PCa-specific mortality, in particular with the use of hydrophilic statins.

This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients.

This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped.

The authors aimed to determine the effect of phosphodiesterase type 5 inhibitors on penile functioning following prostate surgery. 

This study compared intermittent versus continuous androgen deprivation therapy (ADT) for localized (confined) prostate cancer due to prostate-specific antigen (PSA) elevation after radiotherapy. Main findings: Intermittent ADT was not inferior compared to continuous therapy with respect to survival. However, some quality of life measures, such as fatigue, urinary problems, hot flashes, libido and erectile function, showed some improvement.

The authors determined the effect of hormone therapy on hot flash interference in prostate cancer patients. 

The present study evaluated the effects of hormonal therapy drugs on cardiovascular events in patients with prostate cancer. 

This review evaluated current DNA based vaccination trials focusing on the treatment of prostate cancer.

The authors determined the link between a specific hormone therapy and the risk of pneumonia in prostate cancer patients.